3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
307
Pancreatic Neoplasms
206
Stomach Neoplasms
162
Carcinoma, Hepatocellular
160
Colonic Neoplasms
115
Rectal Neoplasms
104
Esophageal Neoplasms
91
Carcinoma, Non-Small-Cell Lung
91
Breast Neoplasms
76
Neoplasms
67
Liver Neoplasms
62
Ovarian Neoplasms
60
Melanoma
51
Neoplasm Metastasis
50
Cholangiocarcinoma
49
Lung Neoplasms
48
Squamous Cell Carcinoma of Head and Neck
37
Esophageal Squamous Cell Carcinoma
37
Gastrointestinal Neoplasms
36
Carcinoma, Renal Cell
35
Prostatic Neoplasms
33
Uterine Cervical Neoplasms
32
Sarcoma
32
Endometrial Neoplasms
32
Biliary Tract Neoplasms
31
Anus Neoplasms
30
Head and Neck Neoplasms
27
Urinary Bladder Neoplasms
22
Triple Negative Breast Neoplasms
21
Adenocarcinoma Of Esophagus
21
Interventions
trifluridine tipiracil drug combination
1
reolysin
1
atezolizumab
1
Gemcitabine
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Anal Cancer Metastatic
×
Gastrointestinal
×
Clear all
NCT07280377
2026-05-19
GOBLET
Oncolytics Biotech
Phase 1/2
Active not recruiting
122 enrolled